Lars Fruergaard Jørgensen, Novo Nordisk CEO, at EUBIO21
February 2, 2022 09:53 AM EST
Pharma

No­vo surges on up­beat Q4 re­view and a move to pro­duce We­govy in-house. But charge of in­sulin price ma­nip­u­la­tion lingers

John Carroll

Editor & Founder

No­vo Nordisk shares $NO­VO surged close to 3% on Wednes­day morn­ing as ris­ing prof­its, a key beat on the num­bers and ev­i­dence that the phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times